Physician profile
James J Devoursney
NPI 1871696021
$5,272.14
in general payments reported to CMS, 2019-2025
35 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $189 · 2021: $502 · 2022: $543 · 2023: $668 · 2024: $1,236 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.88 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.87 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $509.88 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $497.56 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $402.11 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $379.35 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $298.69 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Genzyme Corporation | $294.16 | 2019-2025 | |
| Organogenesis INC. | $239.81 | 2019-2025 | Puraply, Cygnus Dual |
| Novartis Pharmaceuticals Corporation | $221.39 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $192.34 | 2019-2025 | Odomzo, Blu-U |
| Pfizer INC. | $169.77 | 2021-2025 | |
| Incyte Corporation | $143.34 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.01 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $99.46 | 2022-2024 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $95.96 | 2020-2021 | |
| Revance Therapeutics, INC. | $89.57 | 2024 | Daxxify |
| Prugen, INC. Pharmaceuticals | $86.81 | 2019 | |
| Lilly USA, LLC | $84.72 | 2019-2025 | Ebglyss |
| Genentech USA, INC. | $81.59 | 2019-2021 | |
| Almirall LLC | $75.67 | 2019-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $75.26 | 2023-2025 | Sotyktu |
| Amgen INC. | $71.30 | 2022-2024 | Otezla |
| Smith+Nephew, INC. | $42.58 | 2020-2023 | Grafix Pl |
| Celgene Corporation | $40.97 | 2019 | |
| Kyowa Kirin, INC. | $27.12 | 2025 | |
| Organon LLC | $23.81 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $21.14 | 2022 | |
| Convatec INC. | $20.93 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.08 | 2024 | Ycanth |
| Dermira, INC. | $17.65 | 2020 | |
| Biofrontera INC. | $17.21 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $13.70 | 2023 | |
| Merck Sharp & Dohme LLC | $12.42 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $6.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Devoursney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.